ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,515Medicare Part D Prescriptions Filled, Including Refills

Rank: 231 out of 939

$485K Total Retail Price of All Prescriptions

Rank: 258 out of 939

422 Patients Receiving at Least One Drug in Part D
57%Patients 65 Years and Older
60% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 422 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

27% of this provider’s 422 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

2% of this provider’s 5,543 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
HYDROCODONE-ACETAMINOPHEN 718 308 S3 1 1
LISINOPRIL 450 254 2 3
OMEPRAZOLE 328 195 3 5
LEVOTHYROXINE SODIUM 313 210 4 4
SIMVASTATIN 297 200 5 2
PRAVASTATIN SODIUM 273 142 6 13
FUROSEMIDE 272 177 7 7
AMLODIPINE BESYLATE 269 213 8 6
METFORMIN HCL 259 149 9 8
METOPROLOL TARTRATE 254 170 10 10
ZOLPIDEM TARTRATE 210 108 11 20
POTASSIUM CHLORIDE 208 133 12 9
TRAMADOL HCL 131 56 13 16
SERTRALINE HCL 128 76 14 24
TIZANIDINE HCL 128 42 14 81
GABAPENTIN 126 70 16 11
MELOXICAM 124 58 17 14
CARVEDILOL 122 77 18 25
LISINOPRIL-HYDROCHLOROTHIAZIDE 102 43 19 23
CARISOPRODOL 101 0 R 20 51
PROAIR HFA 99 48 21 41
FLUOXETINE HCL 96 31 22 47
HYDROCHLOROTHIAZIDE 89 29 23 12
TRIAMTERENE-HCTZ 85 58 24 33
CITALOPRAM HBR 85 48 24 15
GEMFIBROZIL 83 50 26 100
CYMBALTA 82 31 27 44
NEXIUM 81 38 28 18
ATENOLOL 80 72 29 19
PAROXETINE HCL 80 31 29 70
FLUTICASONE PROPIONATE 80 43 29 43
METOPROLOL SUCCINATE 79 71 32 21
CYCLOBENZAPRINE HCL 78 13 R 33 36
AZITHROMYCIN 75 39 34 32
SYNTHROID 74 22 35 75
TRAZODONE HCL 73 37 36 26
DICLOFENAC SODIUM 71 42 37 93
GLYBURIDE 70 34 R 38 89
CIPROFLOXACIN HCL 69 41 39 54
ENALAPRIL MALEATE 68 41 40 65
ATORVASTATIN CALCIUM 68 33 40 22
WARFARIN SODIUM 68 50 40 17
DILTIAZEM HCL 66 38 43 217
CLOPIDOGREL 65 46 44 28
LOVASTATIN 63 35 45 46
SPIRIVA 58 41 46 73
SINGULAIR 57 0 47 101
RANITIDINE HCL 55 27 48 35
BENAZEPRIL HCL 54 28 49 87
VENLAFAXINE HCL ER 53 23 50 121
FENTANYL 53 23 S2 50 104
ADVAIR DISKUS 52 34 52 60
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 9, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.